Evolving Use of PARP Inhibitors Requires Biomarker-Driven Approaches for Treatment Selection in Prostate Cancer

Yonsa (abiraterone acetate) - Churchill Pharma, Sun Pharma

Lynparza (olaparib) - Merck (MSD), AstraZeneca

Talzenna (talazoparib) - Pfizer

Vivek K Narayan; Samuel Takvorian; Kayvan Zarrabi; Ronac Mamtani; Jason E Shpilsky; Pooja Ghatalia

Oct 18, 2023